Fu Shan

Fushan Pharmaceutical is a China-based biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. The company specializes in the research and commercialization of treatments for type 2 diabetes, obesity, and related metabolic conditions. Its pipeline features several candidates targeting the GLP-1 pathway, including both small molecule and biologic approaches. Fushan Pharmaceutical aims to address significant unmet medical needs in the metabolic disease space through advanced drug delivery and novel mechanism-of-action strategies. The company maintains a strong presence in the domestic Chinese market while exploring global development opportunities.